Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Hosts US-Chinese Surgeons Academic Exchange Program


Miami, US – MicroPort® Orthopedics recently hosted an academic exchange program for Chinese and US surgeons in Miami of US. During the one-week program, surgeons from Shanghai, Qingdao and Shenzhen closely worked with US experts and discussed together the cutting-edge technologies of joint replacement, centering around MicroPort® Orthopedics' medial pivot knee systems.
The first part of the program was held in Miami Anatomical Research Center. Dr. Burke of Broward Medical Center explained the design rationale, clinical outcome and clinical experience of the medial pivot knee. He pointed out: "The medial compartment is more stable than the lateral compartment in knee flexion, and the mobility provided by the lateral compartment makes the femoral rotation in knee flexion." Designed based on such theories, the medial pivot knee guarantees stability, safety and high flexion compared to the traditional design of knee prostheses. Afterwards, in the cadaver lab, surgeons got hands-on experience with the surgical instrument of EVOLUTION® Medial-Pivot Knee System ("EVOLUTION®") under the direction of Dr. Burke. With the combination of theory and practice, surgeons had better understanding in the medial pivot knee, and many of them spoke highly of the design of the knee system as well as the matching instrument.
The second and the third parts of the program were respectively held in Broward Medical Center and Crestwood Medical Center. In these two medical centers, nearly 800 joint replacement surgeries are performed annually. Surgical observations of total knee arthroplasty with medial pivot knee were specially arranged for Chinese surgeons. Dr. Janssen of Crestwood Medical Center and Dr. Burke perfectly utilized their surgical skills based on the design features of medial pivot knees, and had in-depth discussion with Chinese surgeons regarding incision approach, osteotomy, soft tissue balance, Intraoperative analgesia and perioperative management.
As the second-generation medial pivot knee system of MicroProt® Orthopedics, EVOLUTION® has gained high market recognition after being introduced to the China market. Up to date, over 550,000 medial pivot knees have been implanted globally. According to a study evaluating long-term clinical and radiographic outcomes of the medial pivot knee system published in The Knee, the results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities. MicroPort® Orthopedics will continue to promote such innovative device through trans-border academic activities, so as to drive the development of orthopedic business worldwide and offer better solutions for surgeons and patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Coporate Genearal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® EP Participates in a Free Clinic in Jiangxi
[Next]:MicroPort® Endovascular Attends SJVF-2017